Home / Health / Merck Offers Hope: HIV Pill for 129 Nations
Merck Offers Hope: HIV Pill for 129 Nations
24 Jul
Summary
- Merck signs licensing deals for experimental HIV pill.
- Low-cost versions of the drug will reach 129 countries.
- The once-monthly oral HIV pill is in late-stage development.
Merck has entered into seven voluntary licensing agreements with generic drug manufacturers, paving the way for lower-cost versions of its experimental HIV pill. This significant step aims to broaden access to the once-monthly oral treatment.
The agreements will enable the production and sale of the drug in 129 countries designated as low- and lower-middle-income. This initiative represents a commitment to global health equity.
The experimental drug, known as alimatravir, is currently in the final stages of clinical development. Merck is concurrently investing in scaling up its product manufacturing capabilities to align with the ongoing trials.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
